Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2017

01-05-2017 | Original Paper

PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists

Authors: Andrew E. Petroll, Jennifer L. Walsh, Jill L. Owczarzak, Timothy L. McAuliffe, Laura M. Bogart, Jeffrey A. Kelly

Published in: AIDS and Behavior | Issue 5/2017

Login to get access

Abstract

HIV pre-exposure prophylaxis (PrEP) was FDA approved in 2012, but uptake remains low. To characterize what would facilitate health care providers’ increased PrEP prescribing, we conducted a 10-city, online survey of 525 primary care providers (PCPs) and HIV providers (HIVPs) to assess awareness, knowledge, and experience with prescribing PrEP; and, comfort with and barriers to PrEP-related activities. Fewer PCPs than HIVPs had heard of PrEP (76 vs 98%), felt familiar with prescribing PrEP (28 vs. 76%), or had prescribed it (17 vs. 64%). PCPs were less comfortable than HIVPs with PrEP-related activities such as discussing sexual activities (75 vs. 94%), testing for acute HIV (83 vs. 98%), or delivering a new HIV diagnosis (80 vs. 95%). PCPs most frequently identified limited knowledge about PrEP and concerns about insurance coverage as prescribing barriers. PCPs and HIVPs differ in needs that will facilitate their PrEP prescribing. Efforts to increase PrEP uptake will require interventions to increase the knowledge, comfort, and skills of providers to prescribe PrEP.
Literature
1.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
2.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
3.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
4.
Molina J, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on Retroviruses and Opportunistic Infections. Seattle, 2015 [Abstract 23LB].
5.
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015;387(10013):53–60.CrossRefPubMed
6.
Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.CrossRefPubMedPubMedCentral
7.
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed
8.
Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.CrossRefPubMedPubMedCentral
9.
Mera R, McCallister S, Palmer B, et al. Truvada for HIV pre-exposure prophylaxis (PrEP) utilization in the United States (2013–2015). 21st International AIDS Conference. Durban, 2016 [Abstract TUAX0105LB].
10.
Laufer F, O’Connell DA, Feldman I. Increased Medicaid Prescriptions for Preexposure Prophylaxis Against HIV infection—New York, 2012–2015. MMWR Morb Mortal Wkly Rep. 2015;64(Early Release):1–6.
11.
Smith DK, Mendoza MCB, Stryker JE, Rose CE. PrEP awareness and attitudes in a national survey of primary care clinicians in the United States, 2009–2015. PLoS ONE. 2016;11(6):e0156592.CrossRefPubMedPubMedCentral
12.
Grant R, Hecht J, Raymond H. Scale-up of pre-exposure prophylaxis in San Francisco to impact HIV incidence. Conference on Retroviruses and Opportunistic Infections. Seattle, 2015 [Abstract 25].
13.
Smith DK, Van Handel M, Wolitski RJ, Stryker JE, Hall HI, Prejean J. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1291–5.CrossRefPubMed
14.
Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712–21.CrossRefPubMedPubMedCentral
15.
Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, et al. Knowledge is power! increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10.CrossRefPubMedPubMedCentral
16.
Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013;27(10):553–9.CrossRefPubMed
17.
Tripathi A, Whiteside YO, Duffus WA. Perceptions and attitudes about preexposure prophylaxis among seronegative partners and the potential of sexual disinhibition. South Med J. 2013;106(10):558–64.CrossRefPubMed
18.
Desai M, Gafos M, Dolling D, McCormack S, Nardone A. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2015;15:28.
19.
Adams LM, Balderson B, Packett BJ, Brown K, Catz SL. Providers’ perspectives on prescribing pre-exposure prophlaxis (PrEP) for HIV prevention. HIV Specialist. 2015;7(1):18–25.
20.
Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, Steward WT, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7(7):e40603.CrossRefPubMedPubMedCentral
21.
Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704–12.CrossRefPubMed
22.
Seidman D, Carlson K, Weber S, Witt J, Kelly PJ. United States family planning providers’ knowledge of and attitudes towards preexposure prophylaxis for HIV prevention: a national survey. Contracept. 2016;93(5):463–9.CrossRef
23.
24.
Sachdev DD, Stojanovski K, Liu AY, Buchbinder SP, Macalino GE. Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs. Clin Infect Dis. 2014;58(12):1786–7.CrossRefPubMedPubMedCentral
25.
Mimiaga MJ, White JM, Krakower DS, Biello KB, Mayer KH. Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. AIDS Care. 2014;26(6):684–93.CrossRefPubMed
26.
White JM, Mimiaga MJ, Krakower DS, Mayer KH. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26(7):395–405.PubMedPubMedCentral
27.
Sharma M, Wilton J, Senn H, Fowler S, Tan DH. Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS ONE. 2014;9(8):e105283.CrossRefPubMedPubMedCentral
28.
Krakower DS, Oldenburg CE, Mitty JA, Wilson IB, Kurth AE, Maloney KM, et al. Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS ONE. 2015;10(7):e0132398.CrossRefPubMedPubMedCentral
29.
Smith, D, Mendoza, M, Rose, C. PrEP Awareness and attitudes in a nationally representative survey of primary care clinicians in the United States, 2009–2013. US National HIV Prevention Conference. 2015, Atlanta [Abstract 1686].
30.
Desai M, Gafos M, Dolling D, McCormack S, Nardone A. PROUD study. Healthcare providers’ knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. HIV Med. 2016;17(2):133–42.CrossRefPubMed
31.
Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States–2014: A clinical practice guideline. Atlanta: CDC; 2014.
32.
Centers for Disease Control and Prevention (CDC). HIV Surveillance report, 2014. November, 2015. Report No.: 26.
33.
Calabrese SK, Magnus M, Mayer KH, et al. Putting PrEP into practice: lessons learned from early-adopting US providers’ firsthand experiences providing HIV pre-exposure prophylaxis and associated care. PLoS ONE. 2016;11(6):e0157324.CrossRefPubMedPubMedCentral
34.
Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68:337–44.CrossRefPubMed
35.
Metadata
Title
PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists
Authors
Andrew E. Petroll
Jennifer L. Walsh
Jill L. Owczarzak
Timothy L. McAuliffe
Laura M. Bogart
Jeffrey A. Kelly
Publication date
01-05-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1625-1

Other articles of this Issue 5/2017

AIDS and Behavior 5/2017 Go to the issue

Original Paper

What Messages are Adolescent Voluntary Medical Male Circumcision (VMMC) Clients Getting and How? Findings From an Observational Study in Tanzania

Original Paper

Correlates of Enhanced Sexual Pleasure from Condom Use: A Study of Young Black Men Who Have Sex with Men in the United States

Original Paper

The Importance of Sexual History Taking for PrEP Comprehension Among Young People of Color

Original Paper

Predicting Primary and Secondary Abstinence Among Adolescent Boys and Girls in the Western Cape, South Africa

Original Paper

Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature

Original Paper

Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits